Sanofi lifts profit outlook on strong Dupixent sales
Sanofi reported Q3 earnings of €3.55 per share, beating estimates by €2.04, with revenue up 16.2% YoY to €14.44B. Strong sales from Dupixent (€5.7B) and new drugs drove growth. Sanofi raised its 2026 outlook, expecting low-teens sales growth and mid-teens EPS growth at constant exchange rates.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise suggest a bullish short-term catalyst for the stock.
Market read
First report of Sanofi's earnings beat and guidance lift, a material event for a large-cap pharma.
What to watch
Vaccine sales are declining, which could offset some of the upside from Dupixent.
Background
Sanofi reported Q3 2026 results with earnings per share of €3.55, beating estimates, and strong growth in its launch portfolio.
Ticker impact
Sanofi raised its 2026 full-year sales and EPS guidance after Q3 earnings beat and strong Dupixent sales.
likely upward pressure as investors price in higher sales and earnings outlook
The company reported a 34.8% jump in Dupixent sales and beat earnings per share estimates, prompting a lift in full-year guidance, which typically drives buying interest.
Market effects
Strengthens the pharmaceutical sector outlook, especially for companies with immunology pipelines.
Boosts European healthcare stocks as Sanofi is a major French pharma player.
Positive guidance from a large-cap pharma may lift global biotech sentiment.
Counterpoint
If Dupixent growth slows later in the year, the guidance lift could be premature.
Key entities
- companySanofi
French pharmaceutical giant
- productDupixent
Blockbuster immunology drug driving sales growth
